Atria Investments Inc Acquires 1,971 Shares of Ascendis Pharma A/S $ASND

Atria Investments Inc grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 80.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,416 shares of the biotechnology company’s stock after purchasing an additional 1,971 shares during the period. Atria Investments Inc’s holdings in Ascendis Pharma A/S were worth $762,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ASND. Compagnie Lombard Odier SCmA acquired a new stake in Ascendis Pharma A/S during the second quarter worth approximately $39,000. Brooklyn Investment Group raised its holdings in Ascendis Pharma A/S by 332.9% in the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 273 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares during the period. LVW Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth $202,000. Finally, Dearborn Partners LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter worth $203,000.

Ascendis Pharma A/S Price Performance

ASND stock opened at $197.74 on Friday. The stock has a market cap of $12.20 billion, a price-to-earnings ratio of -38.32 and a beta of 0.44. The company has a 50 day simple moving average of $201.67 and a 200 day simple moving average of $183.36. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ASND has been the subject of several recent analyst reports. Cantor Fitzgerald upped their price objective on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the stock an “overweight” rating in a research report on Monday, October 13th. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price target on the stock. Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Finally, UBS Group restated a “buy” rating and set a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $249.80.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.